GT Biopharma, Inc. Regains Nasdaq Minimum Bid Price Compliance

What Happened
GT Biopharma, Inc. (GTBP) announced in an 8-K that Nasdaq notified the company on September 22, 2026 that it had regained compliance with the Nasdaq Capital Market minimum bid price requirement (Rule 5550(a)(2)). The company had been notified on November 20, 2025 that its common stock had closed below $1.00 for 30 consecutive business days and was out of compliance, and Nasdaq had later granted a 180-calendar-day compliance period on May 20, 2026 (ending November 16, 2026).

Key Details

• Nasdaq deficiency notice received: November 20, 2025 (below $1.00 closing bid for 30 consecutive business days).
• Compliance extension granted: May 20, 2026 — additional 180 days, to November 16, 2026.
• Regained compliance notice received: September 22, 2026, after the common stock maintained a closing bid > $1.00 for at least ten consecutive business days.
• Security: Common stock, $0.001 par value per share.

Why It Matters
Regaining compliance means GT Biopharma has satisfied Nasdaq’s minimum bid price requirement and is no longer in non-compliance on that specific technical listing standard. For investors, this reduces the immediate risk of a Nasdaq delisting action related to the minimum bid price deficiency and preserves the company’s continued listing on the Nasdaq Capital Market while other corporate or financial matters remain unchanged.